PROSPECTIVE EVALUATION OF CALCIUM AND ESTROGEN ADMINISTRATION ON BONE MASS AND METABOLISM AFTER OVARIECTOMY

被引：5

作者：

GAMBACCIANI, M

SPINETTI, A

TAPONECO, F

CIAPONI, M

CIMA, GP

TETI, GC

GENAZZANI, AR

机构：

[1] Department of Obstetrics and Gynecology 'Piero Fioretti', University of Pisa

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1995年 / 9卷 / 02期

关键词：

OSTEOPOROSIS; OVARIECTOMY; ETHINYLESTRADIOL; PREVENTION; CALCIUM;

D O I：

10.3109/09513599509160202

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated the effects of low-nose ethinylestradiol administration in the prevention of the rapid bone loss that follows ovariectomy in women. After 10-30 days from surgery, patients received either a sole calcium supplementation 500 mg/day (n = 20) or ethinylestradiol 20 mu g/day in addition to the same daily calcium supplement (n = 21), for 12 months. in the control group, urinary hydroxyproline excretion, serum alkaline phosphatase and plasma bone Gla protein levels presented a substantial (p < 0.05) increase, while radial bone density significantly (p < 0.05) decreased 6 months after surgery. In the ethinylestradiol-treated group, the patterns of biochemical markers indicated that ethinylestradiol can restrain the bone remodelling processes. Radial bone density showed no significant modification during the 12 months' study period. In conclusions, these results demonstrate that the administration of 20 mu g/day of ethinylestradiol can prevent the vapid bone loss that follows ovariectomy.

引用

页码：131 / 135

页数：5

共 26 条

[1]

Gambacciani M., Spinetti A., De Simone L., Cappagli B., Maffei S., Taponeco F., Fioretti P., The relative contribution of menopause and aging to postmenopausal vertebral osteopenia, J. Clin. Endocrinol. Metab, 77, pp. 1148-1151, (1993)

[2]

Wallach S., Henneman P.H., Prolonged estrogen therapy in postmenopausal women, J. Am. Med. Assoc, 171, pp. 1637-1639, (1959)

[3]

Lindsay R., Estrogen therapy in the prevention and management of osteoporosis, Am. J. Obstet. Gynecol, 156, pp. 1347-1349, (1987)

[4]

Whitcroft S.I.J., Stevenson J.C., Hormone replacement therapy: risks and benefits, Clin. Endocrinol, 36, pp. 15-19, (1992)

[5]

Nilas L., Christiansen C., The pathophysiology of peri- and postmenopausal bone loss, Br. J. Obstet. Gynaecol, 96, pp. 580-587, (1989)

[6]

Gambacciani M., Spinetti A., Taponeco F., Cappagli B., Maffei S., Manetti P., Piaggesi L., Fioretti P., Bone loss in perimenopausal women: a longitudinal study, Maturitas, 18, pp. 191-197, (1994)

[7]

Shargil A.A., Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study, Int. J. Fertil, 30, pp. 15-28, (1985)

[8]

Lindsay R., Tohme J., Kanders B., The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women, Contraception, 34, pp. 333-340, (1986)

[9]

Volpe A., Silferi M., Genazzani A.D., Genaz-Zani A.R., Contraception in older women, Contraception, 47, pp. 229-239, (1993)

[10]

Gambacciani M., Spinetti A., Taponeco F., Cappagli B., Piaggesi L., Fioretti P., Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low dose oral contraceptive preparation on bone mineral density and metabolism, Obstet. Gynecol, 83, pp. 392-396, (1994)

← 1 2 3 →